SAVE: Risk of total mortality associated with reduced kidney function

Slides:

Advertisements

Similar presentations

Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.

Advertisements

Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract /477169/465253/454771/ /4146.

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Section 3: CKD, CVD and mortality. Cardiovascular diseases in CKD patients Damage to the heart (Uraemic cardiomyopathy ) Damage to the arteries (Uraemic.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.

Renal Replacement Therapy for Prevention of Contrast- induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials Source Song K, Jiang.

Antonio Coca, MD, PhD, FRCP, FESC

Nephrology Journal Club The SPRINT Trial Parker Gregg

Section 4: Managing progression of CKD

The LIVES Sub-analysis

The MASS-DAC Study.

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder.

Chronic Kidney Disease in Diabetes

Melody Sherwood, Peter A McCullough The Lancet Global Health

Section 3: CKD, CVD and mortality

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder.

Adjusted relative mortality risk

Nat. Rev. Nephrol. doi: /nrneph

Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Association between highest tertile for homocysteine and mortality

ASCOT-BPLA: Primary and secondary end points

Relative risk of major events with atenolol vs placebo

Recognition for Conservative Care in Kidney Failure

Melody Sherwood, Peter A McCullough The Lancet Global Health

John P. Middleton, Patrick H. Pun Kidney International

Fung TT, et al. Circulation 2009;119:

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

Volume 72, Issue 10, Pages (November 2007)

RE-MODEL and RE-NOVATE : Total VTE and All-cause Mortality

Predictors of disease progression in patients with CKD

Steven G. Coca, Swathi Singanamala, Chirag R. Parikh

Cystatin C levels and risk of death from all causes

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

D. Batlle, P. Ramadugu, M.J. Soler Kidney International

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Langsford et al. Am J Nephrol 2017;45: (DOI: / )

Patient characteristics: American vs Canadian transplant patients

Baseline Characteristics of the Subjects

Prevalence of microvascular and macrovascular complications compared between cohort 1 and cohort 2 for subjects with type 2 (A, upper panel) and type 1.

Volume 73, Issue 12, Pages (June 2008)

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Time to death from diabetes diagnosis for propensity-matched sample adjusted for age, gender, race, and other conditions. Time to death from diabetes diagnosis.

Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease C.P. Kovesdy, S. Ahmadzadeh,

Volume 73, Issue 8, Pages (April 2008)

Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

Conceptual model of the course of chronic kidney disease (CKD).

Cardiovascular risk in chronic kidney disease

Volume 75, Issue 1, Pages (January 2009)

Comparison of Baseline Characteristics by Primary End Point

Adjusted relative risk Adjusted odds ratio

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Low/moderate intensity statins High intensity statins

Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Increase of physical activity over time associated with lower HF risk

Risk for chronic kidney disease (CKD) among Olmsted County, MN, stone formers and control subjects. Risk for chronic kidney disease (CKD) among Olmsted.

RR (with 95% CI) of total mortality (multivariate-adjusted) by duration of smoking cessation among diabetic women. RR (with 95% CI) of total mortality.

Low/moderate intensity statins High intensity statins

Presentation transcript:

SAVE: Risk of total mortality associated with reduced kidney function GFR (mL/min/1.73m2) Multivariate adjusted risk ratio 95% CI >75 Ref 60-74 1.11 0.86-1.42 45-59 1.24 0.96-1.60 <45 1.81 1.32-2.48 p for trend 0.001 Tokmakova MP et al. Circulation 2004; available at http://circ.ahajournals.org

SAVE: Events prevented by captopril treatment in subjects with and without chronic kidney disease End point With CKD Without CKD CV events prevented per 100 subjects treated with captopril 12.4 5.5 Tokmakova MP et al. Circulation 2004; available at http://circ.ahajournals.org